Identification of a Spike-Specific CD8+ T-Cell Epitope Following Vaccination Against the Middle East Respiratory Syndrome Coronavirus in Humans

Caroline E. Harrer; Leonie Mayer; MVA-MERS-S Study Group; Anahita Fathi; Susan Lassen; My L. Ly; Madeleine E. Zinser; Timo Wolf; Stephan Becker; Gerd Sutter; Christine Dahlke; Marylyn M. Addo

doi:10.1093/infdis/jiad612

Identification of a Spike-Specific CD8⁺ T-Cell Epitope Following Vaccination Against the Middle East Respiratory Syndrome Coronavirus in Humans

Caroline E. Harrer^*
, Leonie Mayer
, MVA-MERS-S Study Group
, Anahita Fathi
, Susan Lassen
, My L. Ly
, Madeleine E. Zinser
, Timo Wolf
, Stephan Becker
, Gerd Sutter
, Christine Dahlke
, Marylyn M. Addo^*

^*Corresponding author for this work

Virology

Research output: Contribution to journal › Article › Academic › peer-review

12 Downloads (Pure)

Abstract

Licensed vaccines against the Middle East respiratory syndrome coronavirus (MERS-CoV), an emerging pathogen of concern, are lacking. The modified vaccinia virus Ankara vector-based vaccine MVA-MERS-S, expressing the MERS-CoV-spike glycoprotein (MERS-S), is one of 3 candidate vaccines in clinical development and elicits robust humoral and cellular immunity. Here, we identified for the first time a MERS-S-specific CD8⁺ T-cell epitope in an HLA-A∗03:01/HLA-B∗35:01-positive vaccinee using a screening assay, intracellular cytokine staining, and in silico epitope prediction. As evidence from MERS-CoV infection suggests a protective role of long-lasting CD8⁺ T-cell responses, the identification of epitopes will facilitate longitudinal analyses of vaccine-induced T-cell immunity.

Original language	English
Pages (from-to)	e327-e332
Journal	Journal of Infectious Diseases
Volume	230
Issue number	2
DOIs	https://doi.org/10.1093/infdis/jiad612
Publication status	Published - 15 Aug 2024

Bibliographical note

Publisher Copyright:
© 2024 The Author(s).

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/infdis/jiad612Licence: CC BY

Identification of a Spike-Specific CD8+ T-Cell Epitope Following Vaccination Against the Middle East Respiratory Syndrome Coronavirus in HumansFinal published version, 614 KBLicence: CC BY

Cite this

Harrer, C. E., Mayer, L., MVA-MERS-S Study Group, Fathi, A., Lassen, S., Ly, M. L., Zinser, M. E., Wolf, T., Becker, S., Sutter, G., Dahlke, C., & Addo, M. M. (2024). Identification of a Spike-Specific CD8⁺ T-Cell Epitope Following Vaccination Against the Middle East Respiratory Syndrome Coronavirus in Humans. Journal of Infectious Diseases, 230(2), e327-e332. https://doi.org/10.1093/infdis/jiad612

@article{4550941e68724851b66842bf394604bd,

title = "Identification of a Spike-Specific CD8+ T-Cell Epitope Following Vaccination Against the Middle East Respiratory Syndrome Coronavirus in Humans",

abstract = "Licensed vaccines against the Middle East respiratory syndrome coronavirus (MERS-CoV), an emerging pathogen of concern, are lacking. The modified vaccinia virus Ankara vector-based vaccine MVA-MERS-S, expressing the MERS-CoV-spike glycoprotein (MERS-S), is one of 3 candidate vaccines in clinical development and elicits robust humoral and cellular immunity. Here, we identified for the first time a MERS-S-specific CD8+ T-cell epitope in an HLA-A∗03:01/HLA-B∗35:01-positive vaccinee using a screening assay, intracellular cytokine staining, and in silico epitope prediction. As evidence from MERS-CoV infection suggests a protective role of long-lasting CD8+ T-cell responses, the identification of epitopes will facilitate longitudinal analyses of vaccine-induced T-cell immunity.",

author = "Harrer, \{Caroline E.\} and Leonie Mayer and \{MVA-MERS-S Study Group\} and Anahita Fathi and Susan Lassen and Ly, \{My L.\} and Zinser, \{Madeleine E.\} and Timo Wolf and Stephan Becker and Gerd Sutter and Christine Dahlke and Addo, \{Marylyn M.\} and Etienne Bartels and Monika Friedrich and Weskamm, \{Leonie M.\} and Swantje Grundlach and Poetsch, \{Joseph H.\} and Till Koch and Stefan Schmiedel and Bart Haagmanns and Thomas Hesterkamp and Verena Kr{\"a}hling and Asisa Volz and Ditt, \{Vanessa A.\} and Melanie Kessler",

note = "Publisher Copyright: {\textcopyright} 2024 The Author(s).",

year = "2024",

month = aug,

day = "15",

doi = "10.1093/infdis/jiad612",

language = "English",

volume = "230",

pages = "e327--e332",

journal = "Journal of Infectious Diseases",

issn = "0022-1899",

publisher = "Oxford University Press",

number = "2",

}

Harrer, CE, Mayer, L, MVA-MERS-S Study Group, Fathi, A, Lassen, S, Ly, ML, Zinser, ME, Wolf, T, Becker, S, Sutter, G, Dahlke, C & Addo, MM 2024, 'Identification of a Spike-Specific CD8⁺ T-Cell Epitope Following Vaccination Against the Middle East Respiratory Syndrome Coronavirus in Humans', Journal of Infectious Diseases, vol. 230, no. 2, pp. e327-e332. https://doi.org/10.1093/infdis/jiad612

Identification of a Spike-Specific CD8⁺ T-Cell Epitope Following Vaccination Against the Middle East Respiratory Syndrome Coronavirus in Humans. / Harrer, Caroline E.; Mayer, Leonie; MVA-MERS-S Study Group et al.
In: Journal of Infectious Diseases, Vol. 230, No. 2, 15.08.2024, p. e327-e332.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Identification of a Spike-Specific CD8+ T-Cell Epitope Following Vaccination Against the Middle East Respiratory Syndrome Coronavirus in Humans

AU - Harrer, Caroline E.

AU - Mayer, Leonie

AU - MVA-MERS-S Study Group

AU - Fathi, Anahita

AU - Lassen, Susan

AU - Ly, My L.

AU - Zinser, Madeleine E.

AU - Wolf, Timo

AU - Becker, Stephan

AU - Sutter, Gerd

AU - Dahlke, Christine

AU - Addo, Marylyn M.

AU - Bartels, Etienne

AU - Friedrich, Monika

AU - Weskamm, Leonie M.

AU - Grundlach, Swantje

AU - Poetsch, Joseph H.

AU - Koch, Till

AU - Schmiedel, Stefan

AU - Haagmanns, Bart

AU - Hesterkamp, Thomas

AU - Krähling, Verena

AU - Volz, Asisa

AU - Ditt, Vanessa A.

AU - Kessler, Melanie

PY - 2024/8/15

Y1 - 2024/8/15

N2 - Licensed vaccines against the Middle East respiratory syndrome coronavirus (MERS-CoV), an emerging pathogen of concern, are lacking. The modified vaccinia virus Ankara vector-based vaccine MVA-MERS-S, expressing the MERS-CoV-spike glycoprotein (MERS-S), is one of 3 candidate vaccines in clinical development and elicits robust humoral and cellular immunity. Here, we identified for the first time a MERS-S-specific CD8+ T-cell epitope in an HLA-A∗03:01/HLA-B∗35:01-positive vaccinee using a screening assay, intracellular cytokine staining, and in silico epitope prediction. As evidence from MERS-CoV infection suggests a protective role of long-lasting CD8+ T-cell responses, the identification of epitopes will facilitate longitudinal analyses of vaccine-induced T-cell immunity.

AB - Licensed vaccines against the Middle East respiratory syndrome coronavirus (MERS-CoV), an emerging pathogen of concern, are lacking. The modified vaccinia virus Ankara vector-based vaccine MVA-MERS-S, expressing the MERS-CoV-spike glycoprotein (MERS-S), is one of 3 candidate vaccines in clinical development and elicits robust humoral and cellular immunity. Here, we identified for the first time a MERS-S-specific CD8+ T-cell epitope in an HLA-A∗03:01/HLA-B∗35:01-positive vaccinee using a screening assay, intracellular cytokine staining, and in silico epitope prediction. As evidence from MERS-CoV infection suggests a protective role of long-lasting CD8+ T-cell responses, the identification of epitopes will facilitate longitudinal analyses of vaccine-induced T-cell immunity.

UR - https://www.scopus.com/pages/publications/85201437577

U2 - 10.1093/infdis/jiad612

DO - 10.1093/infdis/jiad612

M3 - Article

C2 - 38195212

AN - SCOPUS:85201437577

SN - 0022-1899

VL - 230

SP - e327-e332

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

IS - 2

ER -